Key Insights

Highlights

Success Rate

88% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

9.4%

3 terminated out of 32 trials

Success Rate

88.0%

+1.5% vs benchmark

Late-Stage Pipeline

28%

9 trials in Phase 3/4

Results Transparency

23%

5 of 22 completed with results

Key Signals

5 with results88% success

Data Visualizations

Phase Distribution

27Total
Not Applicable (11)
P 1 (5)
P 2 (2)
P 3 (6)
P 4 (3)

Trial Status

Completed22
Unknown3
Terminated3
Recruiting2
Withdrawn1
Active Not Recruiting1

Trial Success Rate

88.0%

Benchmark: 86.5%

Based on 22 completed trials

Clinical Trials (32)

Showing 20 of 20 trials
NCT06626321Not ApplicableCompleted

Behavioral Economics to Improve Flu Vaccination Using EHR Nudges Replication

NCT06158659Not ApplicableCompletedPrimary

Improved Immunology Outcomes Associated With Lactoferrin Fortified With HMO in Infant Formula

NCT04515446Not ApplicableActive Not RecruitingPrimary

Quantification of Viral Load in the Upper Respiratory Tract in Patients Treated With Olsetamivir for Influenza

NCT07147517Recruiting

Preparedness Through Respiratory Virus Epidemiology and Community Engagement

NCT04153331Not ApplicableCompleted

Burden of Influenza at Emergency Department Level : BIED

NCT07007377Recruiting

Can the Ergometric Test in Flu-like Syndrome Help in the Outcome Analysis of Unvaccinated Patients

NCT06057727Not ApplicableCompleted

Behavioral Economics to Improve Flu Vaccination Using EHR Nudges

NCT03694808Phase 4CompletedPrimary

FLUAD vs. FLUZONE HD Influenza Vaccine in Residents of Long Term Care

NCT06385821Phase 3Completed

A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus

NCT03212716Phase 2TerminatedPrimary

Efficiency of Antagonist Drugs of the Cellular Transcriptomic Signature of Influenza A Virus Infection.

NCT03430089Phase 1Completed

Safety of a Single Dose or Two Doses of Shenzhen Quadrivalent Influenza Vaccine

NCT05435144Not ApplicableUnknown

Elderberry for Immune Support

NCT05473325Unknown

Benchtop NMR Spectroscopy for Assessment of Clinical Human Pathologies (BRANCH-P STUDY)

NCT05417997Phase 3Completed

Effect of Kunamin in SARS-CoV-2 RT-PCR Positive Covid-19 Patients

NCT03344029Phase 4Completed

Immunogenicity and Safety of the Shenzhen Trivalent Inactivated Influenza Vaccine Versus a Trivalent Influenza Vaccine Comparator in Chinese Subjects 18 to 59 Years

NCT03308825Phase 4Completed

Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines

NCT03769012Not ApplicableCompleted

Ability of Beta-glucan Supplementation to Augment Immune Function

NCT00769002Not ApplicableTerminatedPrimary

PET-CT Scans in Healthy Volunteers After Flu Vaccination

NCT02822105Phase 1CompletedPrimary

Safety and Immunogenicity Study of H3N2 M2SR Monovalent Influenza Vaccine in Healthy Volunteers

NCT02037282Phase 1Withdrawn

A Phase 1, Open Label, Ascending Dose Cohort Study of the Pharmacokinetics of Anti-Influenza Hyperimmune Intravenous Immunoglobulin in Healthy Subjects

Scroll to load more

Research Network

Activity Timeline